Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors
Keith M Skubitz* 1, Stefan Pambuccian2, J Carlos Manivel2 and Amy PN Skubitz2

Address: 1Department of Medicine, the University of Minnesota Medical School, Masonic Cancer Center, Minneapolis, MN 55455, USA and 2Department of Laboratory Medicine and Pathology, the University of Minnesota Medical School, Masonic Cancer Center, Minneapolis, MN 55455, USA

Email: Keith M Skubitz* - skubi001@tc.umn.edu; Stefan Pambuccian - pambu001@umn.edu; J Carlos Manivel - maniv001@umn.edu; Amy PN Skubitz - skubi002@umn.edu

* Corresponding author

Abstract
The heterogeneity that soft tissue sarcomas (STS) exhibit in their clinical behavior, even within histological subtypes, complicates patient care. Histological appearance is determined by gene expression. Morphologic features are generally good predictors of biologic behavior, however, metastatic propensity, tumor growth, and response to chemotherapy may be determined by gene expression patterns that do not correlate well with morphology. One approach to identify heterogeneity is to search for genetic markers that correlate with differences in tumor behavior. Alternatively, subsets may be identified based on gene expression patterns alone, independent of knowledge of clinical outcome. We have reported gene expression patterns that distinguish two subgroups of clear cell renal carcinoma (ccRCC), and other gene expression patterns that distinguish heterogeneity of serous ovarian carcinoma (OVCA) and aggressive fibromatosis (AF).
In this study, gene expression in 53 samples of STS and AF [including 16 malignant fibrous histiocytoma (MFH), 9 leiomyosarcoma, 12 liposarcoma, 4 synovial sarcoma, and 12 samples of AF] was determined at Gene Logic Inc. (Gaithersburg, MD) using Affymetrix GeneChip® U_133 arrays containing approximately 40,000 genes/ESTs. Gene expression analysis was performed with the Gene Logic Genesis Enterprise System® Software and Expressionist software. Hierarchical clustering of the STS using our three previously reported gene sets, each generated subgroups within the STS that for some subtypes correlated with histology, and also suggested the existence of subsets of MFH. All three gene sets also recognized the same two subsets of the fibromatosis samples that we had found in our earlier study of AF. These results suggest that these subgroups may have biological significance, and that these gene sets may be useful for sub-classification of STS. In addition, several genes that are targets of some anti-tumor drugs were found to be differentially expressed in particular subsets of STS.

Introduction
Soft tissue sarcomas (STS) exhibit heterogeneity in their clinical behavior, even within the same histological subtypes. This heterogeneity is an important problem in the treatment of patients with STS. Gene expression is felt to play a critical role in cell development and malignant
transformation, and gene expression profiles are of potential use in the classification and diagnosis of malignancies [1-3]. Several recent studies have found distinctive gene expression patterns that can differentiate between histologic subtypes of STS [4-10].

Histological appearance is determined by gene expression. However, metastatic propensity, tumor growth, and response to therapy may be determined by gene expression patterns that do not correlate well with morphology. One approach to identify heterogeneity is to search for markers that correlate with differences in tumor behavior. Alternatively, subsets may be identified based on gene expression patterns independent of knowledge of clinical outcome. We have reported gene expression patterns that distinguish two subsets of clear cell renal cell carcinoma (ccRCC) [11], two major subgroups of aggressive fibromatosis (AF) [12], and other patterns that distinguish borderline from invasive serous ovarian carcinoma (OVCA) [13].

In the current study, we sought to identify subsets of STS based on patterns of gene expression using these three gene sets. We also searched for the expression of genes that encode targets of selected therapies in different STS subsets. Gene expression levels were quantified by the use of microarray technology using the Affymetrix GeneChip® U_133 microarray, representing ~40,000 known genes and expression sequence tags (ESTs). Hierarchical clustering of the STS using our three previously reported gene sets, each generated subgroups within the STS that for some, but not all, subtypes correlated with histology. The term "malignant fibrous histiocytoma" (MFH) is currently used for pleomorphic sarcomas without identifiable differentiation [14]. However, MFH may not represent a distinct tumor entity; indeed many sarcomas previously termed MFH appear to share biochemical markers with other subtypes of STS, but are not readily recognized as such based on their histologic appearance. In this study, we also searched for potential subsets among cases that were diagnosed as MFH. In a set of 16 MFH samples, two major subsets were identified on the basis of gene expression.

We conclude that gene expression profiles may be useful in sub-classifying STS. In addition, differences in gene expression patterns may help identify potential therapies in STS.

Materials and methods

Tissue samples

Tissue from 53 soft tissue tumors, including 41 sarcomas and 12 AF (see additional file 1), were obtained from the University of Minnesota Cancer Center's Tissue Procurement Facility. Samples were obtained using protocols approved by the University of Minnesota Institutional Review Board. Tumor samples were identified by a pathologist, dissected ensuring the presence of gross tumor and the absence of necrosis, and snap frozen in liquid nitrogen within 30 min of excision. Parallel tissue sections of each sample were processed routinely, and were examined by light microscopy after H&E staining to confirm the histologic nature of the sample. In addition, diagnoses were also confirmed by the Tissue Procurement Facility pathologist and by a separate review by a pathologist at Gene Logic Inc. (Gaithersburg, MD).

Pathology review and grading

Slides of the STS and AF tumors from which samples had been obtained were reviewed independently by two pathologists experienced in the field of STS without knowledge of their gene expression profiles. All slides available from primary tumors and implants/metastases were reviewed, without knowledge of the original diagnosis or the clinical characteristics of the patients, and assigned a histologic type and grade. Histologic type was determined according to the WHO [15]. The mitotic rate was determined by counting mitoses in 50 high-power fields (HPF) and averaged mitotic counts for 10 HPF. Necrosis was estimated from both the gross description of the tumor and review of all available slides. Histologic grading was performed according to the National Cancer Institute (NCI) system proposed in 1984 by Costa [16] and the updated version of the European system (FNCLCC) [17]. In brief, the NCI system employs three grades based on a combination of histologic diagnosis, cellularity, cellular pleomorphism, mitotic activity and tumor necrosis. A variation of the Costa grading system (as described by Kandel et al [18]) was used, where a score of 1 was assigned to each of the following features: > 6 mitoses/10 HPF, presence of cellular pleomorphism, presence of high tumor cellularity (> 50% cells to matrix), and > 15% tumor necrosis. Tumors with a cumulative score of 1 were assigned grade 1, those with a score of 2 were assigned grade 2, and those with a score of >/= 3 were grade 3. The FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer) system also employs three grades. Briefly summarized, the FNCLCC system assigns a score to tumor differentiation (1: sarcoma closely resembling normal adult mesenchymal tissue; 2: sarcoma for which the histologic typing is certain; 3: embryonal and undifferentiated sarcomas; sarcomas of uncertain type), a score for mitotic activity (1: 0–9/10 HPF; 2: 10–19/10 HPF; 3: 20 or more/10 HPF), and a score for tumor necrosis (0: no tumor necrosis; 1: 50% or less necrosis; 2: > 50% necrosis). The histologic grade is 1 for total score 2 or 3; grade 2 for total score 4 or 5; and grade 3 for total score 6, 7 or 8. An attempt to simplify the grading into a two-tiered system of high and low grade tumors has also been pro-
GeneChip® U_133 microarrays according to the standard for target preparation and then hybridized on Affymetrix biotin-labeled cRNA. Biotinylated cRNA was fragmented transcription using biotinylated ribonucleotides to generate stranded cDNA was used as the template for cDNA followed by second strand synthesis. Double-strand protocols. Briefly, RNA was converted to first strand cDNA followed by second strand synthesis. Double-stranded CDNA was used as the template for in vitro transcription using biotinylated ribonucleotides to generate biotin-labeled cRNA. Biotinylated cRNA was fragmented for target preparation and then hybridized on Affymetrix GeneChip® U_133 microarrays according to the standard Affymetrix protocols. Following hybridization, the microarrays were washed and stained using an automated fluidics system. The microarrays were then digitally scanned and images of the average probe intensities were visually monitored for any irregularities in the microarrays. Samples were rehybridized when images appeared flawed in any way.

The integrity of the RNA sample was further monitored by examining the relative expression of a probe from the 3' end of beta-actin compared with the expression of a probe from the 5' end of the same gene. In addition, internal controls were provided on each Affymetrix microarray, and samples with "flawed" data were not utilized. The geometric means of the expression intensities of the relevant gene fragments were computed, and the ratio was reported as the fold change (up or down). Confidence intervals and p values on the fold change were calculated using a two-sided Welch modified two-sample t-test. Differences were considered significant when p ≤ 0.05. Principle Component Analysis (PCA), contrast analyses, and e-Northern® analyses were performed using the Gene Logic Genesis Enterprise System® Software. Clustering was performed using the Eisen clustering software and viewed using the Tree View software.

**Results**

**Identification of AF subsets**

In a previous study we reported that a set of AF samples could be separated into two major subgroups, AF-1 to AF-5 (AF-set A) and AF-6 to AF-12 (AF-set B), as determined by gene expression patterns [12]. We identified a set of 200 gene fragments most differentially expressed between the two subsets of AF (AF gene set). We recently performed a similar series of gene expression analyses in a set of ccRCC, and identified two major subgroups of ccRCC [11]. Hierarchical clustering using the 167 gene fragments most differentially expressed between the two ccRCC subsets previously reported (RCC gene set) separated the AF samples into two major groups (Fig 1, top). In similar studies, we identified 200 gene fragments most differentially expressed between borderline and invasive OVCA (OVCA gene set) [13]. Similarly, hierarchical clustering of the AF samples using the OVCA gene set separated the AF samples into the same two major groups (Fig 1, bottom). Only 9 genes were present in both the RCC and OVCA gene sets, 16 genes in both the RCC and AF gene sets, and 4 genes in both the OVCA and AF gene sets (Table 1).

To better characterize the potential differences in expression of genes involved in specific signaling pathways and potential therapeutic targets, a series of gene sets were examined for differential expression between AF-set A (AF 1–5) and AF-set B (AF 6–12). First we examined a gene set for wnt-signaling, since differential expression in AF samples of some genes involved in wnt-signaling has been previously reported [12,20–27]. We found many genes involved in the wnt-signaling pathway to be differentially expressed in AF-set A compared with AF-set B. The genes that were up-regulated 4-fold or more in AF-set B are shown in Table 2. None were up-regulated in AF-set A.

Next we compared the expression of genes encoding known growth factors, receptors, cytokines, proteins involved in the immune response, and signaling pathways, including angiogenesis and mTOR in AF-set A compared with AF-set B. The genes that were up-regulated 3-fold or more in AF-set B compared to AF-set A are listed in additional file 2. TGFBI1, TGFBI2, TGFBI3, TGBFR1, TGBFR2, IGF1, IGF2BP3, IGF2BP4, IGF2BP7, HDGF, PDGEC, PDGFRA, PDGFBR, HIF1A, EDNRA, CTGF, LEPR, and as previously reported, FAP and ADAM12, were all over-expressed in AF-set B compared with AF-set A. Genes involved in the initiation of translation were also differentially expressed in AF-set B compared with AF-set A.

**Identification of STS subsets**

We questioned whether these same gene sets might distinguish subgroups of STS independent of histologic diagno-
Figure 1
Clustering of gene expression in the aggressive fibromatosis samples using the RCC gene set (top) and OVCA gene set (bottom) and the Eisen clustering software Cluster. The 12 AF samples were clustered using the Eisen clustering software Cluster and the set of 167 gene fragments from the U_133 microarray set most differentially expressed between two groups of ccRCC previously described [11] (top) and the set of 200 gene fragments most differentially expressed between borderline and invasive OVCA [13] (bottom) as described in the text. Samples AF-1 to AF-5 formed a cluster, while samples AF-6 to AF-12 formed another cluster. The tissue samples in the tree are joined by very short branches if they have gene expression patterns that are very similar to each other, and by increasingly longer branches as their similarity decreases.
sis. Hierarchical clustering was performed with the 12 AF samples, 4 synovial sarcomas, 7 myxoid liposarcomas, 5 other liposarcomas, and 9 leiomyosarcomas using the RCC gene set (Fig 2A), the OVCA gene set (Fig 2B), and the AF gene set (Fig 2C). Two major subgroups were observed in each case. With the RCC gene set (Fig 2A), one subgroup (solid circles and squares) contained 7 AF samples (AF-set B, i.e. AF-6 to AF-12) (solid squares), 4 leiomyosarcoma samples (solid circles), 1 myxoid liposarcoma (solid circle), and 1 round cell liposarcoma (solid circle). When hierarchical clustering was done using the OVCA gene set and the AF gene set (Fig 2B and 2C, respectively), this subgroup contained 3 additional samples (solid triangles) (1 round cell liposarcoma, 1 myxoid liposarcoma, and 1 other liposarcoma). The other major subgroup (open circles and squares), contained five AF samples (AF-set A, i.e. AF-1 to AF-5) (open squares), all four synovial sarcomas, the majority of the myxoid liposarcomas and leiomyosarcomas, and two other liposarcomas.

Since the results of hierarchical clustering are dependent on the composition of the sample sets, hierarchical clustering was then performed using the same three gene sets with the 25 STS samples, but without the AF samples (Fig 3). A similar clustering of the STS samples was again observed, whereby a subgroup consisting of the same four leiomyosarcoma samples, one myxoid liposarcoma, and one round cell liposarcoma (solid circles) clustered together, frequently with the three additional samples (solid triangles). Also, LMS-7 was now included in this cluster using all three gene sets.

Because MFH is not universally recognized as a diagnostic entity, and since STS with the diagnosis of MFH can have different biological behavior, we performed hierarchical clustering of the 16 MFH samples using the 3 gene sets. Hierarchical clustering using the RCC gene set generated two major subsets (Fig 4A), hereafter termed MFH-A (MFH-1 to MFH-9, indicated by an asterisk) and MFH-B (MFH-10 to MFH-16). Hierarchical clustering of the MFH samples using the OVCA gene set (Fig 4B), and the AF gene set (Fig 4C) also generated two clusters of the MFH samples similar to those described above. Since protein kinases are involved in many signaling pathways, hierarchical clustering of the MFH samples was performed using a set of 1500 probes that represent genes that encode protein tyrosine-, serine-, and threonine-kinases; these same two major clusters were again observed (Fig 4D). Each MFH subset appeared to contain a group of four MFH samples (MFH-12 to MFH-15) that were more closely clustered with each other than to the remaining samples of the subset. Because these subclusters contained only four samples, they were not further analyzed separately.

While more than two biologically distinct subsets of the 16 MFH samples likely exist, we focused our subsequent studies on differences between the two major subsets, MFH-A and MFH-B, defined above. A fold change analysis was performed comparing MFH-A to MFH-B. Those genes expressed at >/= 2-fold more between the two sets were then evaluated by e-Northern® analysis. e-Northern® analysis provides a graphical representation of the expression values for each sample. The genes most differentially expressed between MFH-A and MFH-B are listed in additional file 3. Interestingly, all of these genes were over-expressed in MFA-A compared with MFH-B, while none were over-expressed in MFH-B. Among the differentially expressed genes were genes that encode growth factors, receptors, and genes involved in various signaling pathways that are potential drug targets. For example, the 5.3-fold up-regulation of VEGF in MFH-A vs. MFH-B suggests

### Table 1: Genes expressed in multiple gene sets

| Gene Symbol | RCCa | OVCAb | AFc |
|-------------|------|-------|-----|
| CXCR4       | X    | X     |     |
| GPX3        | X    | X     |     |
| IgL         | X    | X     |     |
| LOC440871   | X    | X     |     |
| MT1G        | X    | X     |     |
| MT1H        | X    | X     |     |
| PRAE        | X    | X     |     |
| SERPINA1    | X    | X     |     |
| ACTN1       | X    |       | X   |
| CD44        | X    |       | X   |
| CKAP4       | X    |       | X   |
| CSPG2       | X    |       | X   |
| DCN         | X    |       | X   |
| FABP5       | X    |       | X   |
| FLNA        | X    |       | X   |
| IGSF4       | X    |       | X   |
| KDEL3       | X    |       | X   |
| MT1E        | X    |       | X   |
| MT1X        | X    |       | X   |
| MT2A        | X    |       | X   |
| PLOD2       | X    |       | X   |
| TMEM45A     | X    |       | X   |
| TUBA3       | X    |       | X   |
| D6S1101, DST| X    |       | X   |
| IGFBP7      | X    |       | X   |
| MEST        | X    |       | X   |
| SULF1       | X    | X     |     |

aGene set that distinguished two subsets of clear cell renal cell carcinoma (ref [11]).
bGene set that distinguished borderline from invasive serous ovarian carcinoma (ref [13]).
cGene set that defined two major subgroups of aggressive fibromatosis (ref [12]).
that the efficacy of treatment directed against VEGF could differ in the two MFH subgroups. In addition, genes involved in the initiation of translation, another potential drug target, were also differentially expressed, (i.e. EIF1, EIF2B1, EIF2S, EIF3S7, EIF3S10, EIF4A1, EIF4B, EIF4G1, were all over-expressed > 2.6-fold in MFH-A compared to MFH-B).

Since heterogeneity of a drug target in a diagnostic category is critical to the outcome of a clinical trial, the expression of known potential target genes in the other types of STS was also examined. The expression of many of these genes, and genes for several tumor antigens that might be relevant in immunotherapy trials, was heterogeneous within diagnostic categories (Tables 3 and 4). For example, while VEGF (not shown) was expressed in all of the STS subtypes, TGFβ1 and FGβ7 (keratinocyte growth factor) were expressed in ~78% of LMS but only ~40% of non-myxoid liposarcoma, while OGRF was expressed in ~43% of myxoid liposarcoma, 100% of non-myxoid liposarcomas, ~67% of leiomyosarcomas, and none of the AF samples. Similarly, as regards the potential use of vaccines and immunotherapy, we observed differential expression of several genes. For example, CTAG2 was expressed in ~60% of the non-myxoid liposarcoma samples, but in none of the LMS, AF, or MFH samples. Also, PRAME was expressed in 100% of the non-myxoid liposarcomas and synovial sarcomas, but none of the AF or MFH-B samples.

Taken together, these data suggest that the AF and MFH sample sets can each be divided into two major subsets. Review of the pathology specimens was performed independently by two pathologists (Table 1), without knowledge of the clustering results. In all but 3 cases of the 40 non-AF cases, both pathologists agreed on high vs low grade. No clear histologic features were identified that correlated with the clusters described above, although the average mitosis score appeared lower in the MFH-A than in MFH-B set.

**Discussion**

STS form a heterogeneous group of malignancies comprised of more than fifty distinct diagnostic categories [28-33]. Histologic criteria are useful in predicting outcome in STS. For example, in a comparative study of the NCI and FNCLCC grading systems in 410 adult patients with non-metastatic STS [17], both systems were of prognostic value for predicting metastases and overall survival, by univariate analysis. By multivariate analysis, high tumor grade, regardless of the system used, large tumor size (10 or more cm), and deep location, had independent prognostic value. Importantly, however, STS often exhibit heterogeneity of biological behavior even within diagnostic categories. This heterogeneity makes the clinical care of patients with these diseases challenging, and may also confound the development of drugs to treat these diseases. Thus, there is a need to move past simple histologic examination in STS trials.
Figure 2
Clustering of gene expression of the STS and AF samples with the RCC gene set (A), OVCA gene set (B), and AF gene set (C). The 12 AF samples and the 25 other STS samples were clustered using the Eisen clustering software Cluster as described in the text. The 16 samples that cluster with AF-1 to AF-5 (open squares) using all 3 gene sets are indicated by open circles. The 6 samples that cluster with AF-6 to AF-12 (solid squares) using all 3 gene sets are indicated by closed circles. The clustering of 3 samples (solid triangles) varied with the gene set. The tissue samples in the tree are joined by very short branches if they have gene expression patterns that are very similar to each other, and by increasingly longer branches as their similarity decreases.
Figure 3
Clustering of gene expression of the STS samples with the RCC gene set (A), OVCA gene set (B), and AF gene set (C). The 25 STS samples were clustered using the Eisen clustering software Cluster as described in the text and are labeled as in Figure 2. The tissue samples in the tree are joined by very short branches if they have gene expression patterns that are very similar to each other, and by increasingly longer branches as their similarity decreases.
The classification of STS has traditionally been determined by light microscopic examination of H&E stained tissues, in which recognizable characteristics are identified in the tumors, and more recently also by the use of genetic techniques [reviewed in [28-33]]. Classification of tumors by gene expression profiles has the potential to provide additional useful information that is free of observer bias and variability, and aid in tumor classification and diagnosis. Analysis of gene expression by microarray also has the potential to identify heterogeneity among STS [4-6,8-10]. While one approach is to search for genes that correlate with clinical outcome, heterogeneity of the sample sets may complicate this search, as predictive genes may differ in different types of tumors. The search for genes that predict a particular behavior may also be complicated by genes whose expression is not relevant to the question of interest. Restriction of the number of genes in an analysis by elimination of irrelevant signals may help, if possible. In addition, relevant signals may or may not be different in different histological categories.

In the current report, potential subsets of STS were identified by gene expression profiles independent of knowledge of biological behavior using gene sets that differed between two subgroups of ccRCC, OVCA, and AF. The current report confirms that gene expression patterns can be used to identify subsets of STS directly, without searching for differences based on clinical correlates. This approach may also allow the identification of potential subsets that could be obscured by searching for patterns that discriminate between two predefined groups determined by a particular clinical outcome. Given the simplicity of the technology, there may be no need to identify the smallest gene set that can be used as a reproducible prognostic factor. Indeed, prognostic information may be lost by such an approach. The differences in gene expression observed between subgroups may reflect intrinsic differences in the tumor cells, differences in the host response to the tumor, or both. It is possible that these differences in gene expression patterns reflect differences in biology of these tumors, although we do not have adequate clinical outcome data to confirm this possibility. It is important to note that hierarchical clustering of any random set of samples using a random gene set may yield what appears to be two major clusters; further studies will be required to determine the reproducibility of the current findings and their potential practical utility.

Our findings, though limited by small sample size, suggest the existence of distinct subgroups within the MFH set. As tumors evolve, sequential mutation and/or epigenetic changes may result in increasing divergence in gene expression and biology from the original tumor. We previously reported that hierarchical clustering of gene expression patterns appeared to cluster some MFH sam-

Figure 4
Clustering of gene expression of the MFH samples with the RCC gene set (A), OVCA gene set (B), AF gene set (C), and the protein kinase gene set (D) as described in the text. The 16 MFH samples were clustered using the Eisen clustering software Cluster as described in the text. MFH-1 to MFH-9 grouped together in panel A and are indicated by an asterisk. The tissue samples in the tree are joined by very short branches if they have gene expression patterns that are very similar to each other, and by increasingly longer branches as their similarity decreases.
ples near samples of liposarcoma, while others appeared to form more distinct clusters [9]. It is possible that analysis of a larger number of samples will identify additional clinically and biologically relevant subsets of MFH.

The current report also demonstrates a wide range among STS subgroups in the expression of genes that code for targets of some therapies. For example, PRAME, CTAG1, and CTAG2 have been reported to be over-expressed in liposarcoma compared with a variety of normal tissues [7], and recent studies have reported the expression of these and other CTAGs in several sarcoma subtypes [34,35]. The current results confirmed our earlier report of over-expression of PRAME, CTAG1 and CTAG2 in liposarcomas using the U_95 array [7] with the newer U_133 array, and also demonstrated that the expression of these potential targets of immunotherapy is heterogeneous among STS. Thus, studies in STS of agents with known targets would be strengthened by stratification by expression of target genes.

Notably, the three earlier studies that suggested the existence of two major subsets of AF, RCC, and OVCA, from which the gene sets used herein were derived, found differences in the expression of many extracellular matrix (ECM) genes between the respective subsets in each of the three diseases. This could be important for several reasons. First, the interaction of tumor cells with ECM proteins can have profound effects on cell biology, regulating signal transduction, apoptosis/anoikis, morphology, and tissue architecture. In this regard, expression of the ECM protein TGFBI has recently been reported to influence paclitaxel sensitivity of ovarian carcinoma cells [36]. ECM proteins can regulate interactions between growth factors and ovarian hormones in mammary epithelial cells, and laminin inhibits estrogen-induced proliferation of breast cancer cells [37]. Interactions with ECM components have been reported to alter TNF-alpha induced changes in endothelial permeability [38], and the ECM proteoglycan decorin can inhibit growth of pancreatic carcinoma cells [39]. Similarly, fibrin clots can promote motility of fibroblasts and endothelial cells, and fibrinogen degrada-

### Table 3: Differential Expression of potential target genes in STS samples

| Gene Symbol | Gene Name                                      | Fragment Name | AF | Liposarcoma | LMS | Myxoid Liposarcoma | MFH |
|-------------|------------------------------------------------|---------------|----|-------------|-----|-------------------|-----|
| CTGF        | connective tissue growth factor                | 209101_at     | 100| 80          | 100 | 100               | 9   |
| EGF         | epidermal growth factor                        | 206254_at     | 8  | 0           | 33  | 0                 | 19  |
| EGFR        | epidermal growth factor receptor               | 232541_at     | 83 | 60          | 67  | 86                | 75  |
| FAP         | fibroblast activation protein, alpha            | 209955_s_at   | 100| 60          | 78  | 29                | 100 |
| FGF13       | fibroblast growth factor 13                    | 205110_s_at   | 67 | 80          | 67  | 71                | 56  |
| FGF18       | fibroblast growth factor 18                    | 231382_at     | 33 | 60          | 0   | 71                | 19  |
| FGF2        | fibroblast growth factor 2 (basic)             | 204422_s_at   | 33 | 40          | 33  | 14                | 31  |
| FGF7        | fibroblast growth factor 7 (keratinocyte growth factor) | 205782_at | 58 | 40          | 78  | 57                | 56  |
| FGFR1       | fibroblast growth factor receptor 1            | 222164_at     | 92 | 80          | 89  | 86                | 94  |
| FGFR2       | fibroblast growth factor receptor 2            | 208228_s_at   | 83 | 40          | 89  | 71                | 50  |
| FLT1        | fms-related tyrosine kinase 1 (vascular endothelial growth factor receptor) | 226497_s_at | 100| 100         | 78  | 100               | 100 |
| IGFI        | insulin-like growth factor 1 (somatomedin C)   | 209541_at     | 100| 100         | 67  | 100               | 94  |
| IGFR2       | insulin-like growth factor 2 receptor          | 201392_s_at   | 67 | 100         | 67  | 43                | 75  |
| MET         | met proto-oncogene (hepatocyte growth factor receptor) | 203510_at | 58 | 60          | 11  | 29                | 75  |
| NGFB        | nerve growth factor, beta polypeptide          | 206814_at     | 25 | 0           | 11  | 14                | 6   |
| OGRF        | opioid growth factor receptor                  | 202841_x_at   | 0  | 100         | 67  | 43                | 75  |
| PDGFA       | platelet-derived growth factor alpha polypeptide| 229830_at     | 17 | 0           | 11  | 0                 | 13  |
| PDGFB       | platelet-derived growth factor beta polypeptide| 216061_x_at  | 42 | 80          | 67  | 86                | 63  |
| PDGFR1      | platelet-derived growth factor receptor, alpha polypeptide | 203131_at | 100| 100        | 67  | 100               | 100 |
| PDGFRB      | platelet-derived growth factor receptor, beta polypeptide | 202273_at | 100| 100        | 89  | 100               | 100 |
| PGF         | placental growth factor, vascular endothelial growth factor-related protein | 215179_x_at | 100| 100        | 100 | 100               | 100 |
| TGFA        | transforming growth factor, alpha              | 205016_at     | 8  | 0           | 22  | 14                | 63  |
| TGFBI       | transforming growth factor, beta 1             | 203085_s_at   | 83 | 40          | 78  | 57                | 100 |
| TGFBI2      | transforming growth factor, beta 2             | 228121_at     | 92 | 60          | 67  | 86                | 81  |
| TGFBI3      | transforming growth factor, beta 3             | 209747_at     | 100| 40          | 89  | 43                | 88  |
tion products may be angiogenic [40,41]. Second, the response of the host to the tumor may also play an important role in tumor biology, and ECM expression, by either tumor cells or host stromal cells, could reflect the local host response. For example, stromal fibroblasts could produce factors that alter tumor cell growth/biology [42].

It would be reasonable to stratify patients entering clinical trials using a technique similar to that described herein, in an attempt to decrease the problem of heterogeneity of the study population. Even if not performed in real time, tumor samples should be saved for a later analysis of this type. Since the results of a clustering analysis depend upon the composition of the sample set analyzed, such an approach would use a standard reference group of STS samples with clustering performed with the addition of the new test sample.

When comparing histologic grading of soft tissue sarcomas and their gene expression, it is important to take into consideration several facts. Histologic grading is an imperfect exercise; when the reproducibility of the European system was tested by 15 pathologists [43], an agreement was reached in 81% of the cases for tumor necrosis, 74% for tumor differentiation, 73% for mitotic rate, and 75% for overall tumor grade, although the agreement for histologic type was only 61%. In a study in which the NCI and FNCLCC grading systems were compared, there were discrepancies in ~35% of the cases [17]. Compared to the NCI system, the FNCLCC system produced a greater number of grade 3 tumors, a lower number of grade 2 tumors, and had better correlation with metastases-free and overall survival. Despite the limitations in reproducibility, numerous studies have confirmed the prognostic value of histologic grading of soft tissue sarcomas [44-46]. Any new technique that attempts to establish new pathways for prognostication should be compared to currently available techniques, and its superiority should be documented. Gene expression profiles, in addition to providing potentially useful prognostic information, may yield insight into two important aspects of sarcoma; namely, the identification of therapeutic targets, leading to more individualized therapies, and second, better understanding of the genesis, progression, and biology of these tumors.

The current study supports the use of gene expression patterns as a complementary set of data that may augment the use of light microscopy to help classify STS. Analysis of a larger number of samples and correlation of biological phenotypes with gene expression patterns may identify clinically meaningful characteristics of the subsets identified herein.

### Competing interests

The authors declare that they have no competing interests.

### Authors' contributions

KMS participated in study design, data analysis, and helped draft the manuscript

SP performed the pathologic examination, and helped analyze data and draft the manuscript

JCM performed the pathologic examination, and helped analyze data and draft the manuscript

APNS helped design the study, analyze data, and draft the manuscript

### Additional material

**Additional file 1**

Samples. Pathologic description of the samples.

Click here for file

[http://www.biomedcentral.com/content/supplementary/1479-5876-6-23-S1.doc](http://www.biomedcentral.com/content/supplementary/1479-5876-6-23-S1.doc)

---

| Gene Symbol | Gene Name                          | AF | Liposarcoma | LMS | Myxoid Liposarcoma | Synovial | MFH-B | MFH-A |
|------------|------------------------------------|----|-------------|-----|-------------------|----------|-------|-------|
| CTAG2      | cancer/testis antigen 2            | 0  | 60          | 0   | 71                | 75       | 0     | 0     |
| CTAGE5     | CTAGE family, member 5             | 75 | 60          | 44  | 29                | 25       | 71    | 67    |
| MAGEA9     | melanoma antigen family A, 9       | 0  | 40          | 111 | 71                | 75       | 14    | 0     |
| MAGED1     | melanoma antigen family D, 1       | 100| 100         | 100 | 100               | 100      | 100   | 100   |
| MAGED2     | melanoma antigen family D, 2       | 100| 80          | 89  | 100               | 50       | 86    | 78    |
| MAGED4     | melanoma antigen family D, 4       | 92 | 80          | 78  | 57                | 100      | 57    | 44    |
| MAGEF1     | melanoma antigen family F, 1       | 92 | 100         | 100 | 100               | 75       | 86    | 78    |
| MAGEH1     | melanoma antigen family H, 1       | 92 | 100         | 100 | 71                | 100      | 86    | 100   |
| PRAME      | preferentially expressed antigen in melanoma | 0  | 100         | 33  | 86                | 100      | 0     | 11    |
Additional file 2
Genes encoding growth factors, receptors, cytokines, and proteins involved in the immune response and signaling pathways upregulated 3-fold or more in AF-set B compared to AF-set A. Genes encoding known growth factors, receptors, cytokines, and proteins involved in the immune response and signaling pathways including angiogenesis and mTOR, that were most differentially expressed between AF-set A and AF-set B are listed. Click here for file
[http://www.biomedcentral.com/content-supplementary/1479-5876-6-23-S2.doc]

Additional file 3
Genes upregulated 3-fold or more in MFH-A compared to MFH-B. Genes that were most differentially expressed between MFH-A and MFH-B were selected by e-Northern analysis and are listed. Click here for file
[http://www.biomedcentral.com/content-supplementary/1479-5876-6-23-S3.doc]

Acknowledgements
We thank Gene Logic Inc., Gaithersburg, MD, for performing the gene expression experiments and providing the GeneExpress® Enterprise System software, and Diane Rauch and Sarah Bowell of the University of Minnesota Ovarian Cancer Alliance, the National Institutes of Health, collecting and processing tissue samples. Supported in part by the Minnesota software, and Diane Rauch and Sarah Bowell of the University of Minnesota Supercomputing Institute.

Presented in part at the 42nd annual meeting of the American Society of Clinical Oncology, June 2–6, 2006 and appears in abstract form, Proc ASCO vol 24, p 538s, 2006.

References
1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos I, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
2. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, Berthold F, Schwab M, Antonescu CR, Peterson C, Meltzer PS: Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001, 7:673-679.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature 2000, 406:746-752.
4. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen Y, Gladfelter AA, Duray PH, Meltzer PS: Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005, 65:9226-9235.
5. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX, Zhu S, Fero M, Sherlock G, Pollack JR, et al: Molecular characteristics of soft tissue tumours: a gene expression study. Lancet 2002, 359:1301-1307.
6. Segal E, Wid掉 P, Antonescu CR, Maki RG, Noble WS, DeSantis D, Woodruff MJ, Lewis JJ, Brennan MF, Houghton AN, Cordon-Cardo C: Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 2003, 163:691-700.
7. Skubitz KM, Cheng EY, Clohisy DR, Thompson RC, Skubitz AP: Differential gene expression in liposarcoma, lipoma, and adipose tissue. Cancer Invest 2005, 23:105-118.
8. Skubitz KM, Skubitz AP: Differential gene expression in leiomyosarcoma. Cancer 2003, 98:1029-1038.
9. Skubitz KM, Skubitz AP: Characterization of sarcomas by means of gene expression. J Lab Clin Med 2004, 144:78-91.
10. West RB, Rijn M van de: The role of microarray technologies in the study of soft tissue tumours. Histopathology 2006, 48:22-31.
11. Skubitz KM, Zimmermann W, Kammerer S, Pambuccian S, Skubitz AP: Differential gene expression identifies subgroups of renal cell carcinoma. J Lab Clin Med 2006, 147:250-267.
12. Skubitz KM, Skubitz AP: Gene expression in aggressive fibromatosis. J Lab Clin Med 2004, 143:89-98.
13. Skubitz AP, Pambuccian SE, Argenza PA, Skubitz KM: Differential gene expression identifies subgroups of ovarian carcinoma. Transl Res 2006, 148:223-248.
14. Tos AP: Classification of pleomorphic sarcomas: where are we now? Histopathology 2006, 48:51-62.
15. Fletcher CDM, Uni KM: World Health Organization Classification of Tumors. Pathology and Genetics fo Tumors of Soft Tissue and Bone Lyon: IARC Press; 2002.
16. Seed J, Wessely RA, Glattstein E, Rosenberg SA: The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer 1984, 53:530-541.
17. Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vitalin MO, Mandard AM, Le Doussal V, Leroux A, et al: Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997, 15:300-362.
18. Kandel RA, Bell RS, Wunder JS, O'Sullivan B, Carton CN, White LM, Davis AM: Comparison between a 2- and 3-grade system in predicting metastatic-free survival in extremity soft-tissue sarcoma. J Surg Oncol 1999, 72:77-82.
19. Skubitz KM, Skubitz AP: Differential gene expression in uterine leiomyoma. J Lab Clin Med 2003, 141:297-308.
20. Abraham SC, Reynolds C, Lee JH, Meltzer PS, Coindre JM, Klimstra DS, Krainskas AM, Wu TT: Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. Hum Pathol 2002, 33:39-46.
21. Alman BA, Li C, Pajkoski ME, Diaz-Cano S, Wolfe HJ: Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997, 151:329-334.
22. Bertario L, Russo A, Sala P, Eboli M, Giarola M, D'Amico F, Gismondi V, Varesco L, Pierotti MA, Radice P: Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 2001, 95:102-107.
23. Cheon SS, Cheahi AY, Turley S, Nadesan P, Poon R, Clevers H, Alman BA: beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci USA 2002, 99:6673-6678.
24. Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirtz H, Cresta S, Kosti NB, Corless CL, et al: Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006, 24:1195-1203.
25. Saito T, Oda Y, Kawaguchi K, Tanaka K, Matsuda S, Tamiya S, Iwamoto Y, Tsuneyoshi M: Possible association between higher beta-catenin mRNA expression and mutated beta-catenin in sporadic desmoid tumors: real-time semiquantitative assay by TaqMan polymerase chain reaction. Lab Invest 2002, 82:97-103.
26. Shiotoh K, Konishi F, Iijima T, Ohdaira T, Sakai K, Kanazawa K, Miyaki M: A novel case of a sporadic desmoid tumour with mutation of the beta catenin gene. J Clin Pathol 1999, 52:695-696.
27. Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, Van Cutsem E, Bapat B, van Roy F, Cossian J, Alman BA: Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatoses (desmoid tumor). Oncogene 1999, 18:6613-6620.
28. Blomgren MP, Alman BA: A novel case of a sporadic desmoid tumour with mutation of the beta catenin gene. J Clin Pathol 1999, 52:695-696.
29. Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, Van Cutsem E, Bapat B, van Roy F, Cassian J, Alman BA: Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatoses (desmoid tumor). Oncogene 1999, 18:6613-6620.
30. Blomgren MP, Alman BA: A novel case of a sporadic desmoid tumour with mutation of the beta catenin gene. J Clin Pathol 1999, 52:695-696.
30. Clark MA, Fisher C, Judson I, Thomas JM: Soft-tissue sarcomas in adults. N Engl J Med 2005, 353:701-711.

31. Demetri GD, Baker LH, Benjamin RS, Casper ES, Conrad EU 3rd, D’Amato GZ, DeLaney TF, Etsinger DS, Heck R Jr, Heslin MJ, et al.: Soft tissue sarcoma. J Natl Compr Canc Netw 2007, 5:364-399.

32. Skubitz KM, D’Adamo DR: Sarcoma. Mayo Clin Proc 2007, 82:1409-1432.

33. Weiss SW, Goldblum JR: Enzinger and Weiss’s Soft Tissue Tumors St. Louis: Mosby; 2001.

34. Ayyoub M, Taub RN, Keohan ML, Hesdorffer M, Metthez G, Memeo L, Mansukhani M, Hibshoosh H, Hesdorffer CS, Vais M, Massie CE, Iyer NG, McGeoch A, Crawford R, et al.: The extracellular matrix protein TGFβ1 induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell 2007, 12:514-527.

35. Segal NH, Blachere NE, Guevara-Patino JA, Gallardo HF, Shiu HY, Viale A, Antonescu CR, Wolchok JD, Houghton AN: Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immun 2005, 5:2.

37. Haslam SZ, Woodward TL: Reciprocal regulation of extracellular matrix proteins and ovarian steroid activity in the mammary gland. Breast Cancer Res 2001, 3:365-372.

38. Partridge CA, Horvath CJ, Del Vecchio PJ, Phillips PG, Malik AB: Influence of extracellular matrix in tumor necrosis factor-induced increase in endothelial permeability. Am J Physiol 1992, 263:L627-633.

39. Koninger J, Giese NA, di Mola FF, Berberat P, Giese T, Esposito I, Bachem MG, Buchler MW, Friess H: Overexpressed decorin in pancreatic cancer: potential tumor growth inhibition and attenuation of chemotherapeutic action. Clin Cancer Res 2004, 10:4776-4783.

40. Tlsty TD, Coussens LM: Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006, 1:119-150.

42. Tsujimoto M, Aozasa K, Ueda T, Morimura Y, Komatsu Y, Doi T: Multivariate analysis for histologic prognostic factors in soft tissue sarcomas. Cancer 1988, 62:994-998.